Rapid screening of EGFR mutations in patients with non-small cell lung cancer, breast cancer and head and neck cancer treated with gefitinib on a compassionate-use program

被引：0
|
作者：
Murray, S
Razis, E
Linardou, H
Lambropoulos, S
Briasoulis, E
Skarlos, D
Pectasides, D
Kalofonos, HP
Papadimitriou, C
Kosmidis, P
Fountzilas, G
机构：
[1] Metropolitan Hosp, Athens, Greece
[2] HYGEIA Med Ctr, Athens, Greece
[3] Ioannina Univ Hosp, Ioannina, Greece
[4] Attikon Univ Hosp, Athens, Greece
[5] Alexandra Univ Hosp, Patras, Greece
[6] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece
[7] Henry Dunan Med Ctr, Athens, Greece
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] EGFR GENE MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER AND ITS INFLUENCE ON EFFECT OF GEFITINIB
    Zhong, W.
    Xia, Y.
    Wang, M-Z
    Chen, M-J
    Zhang, L.
    Zhao, J.
    Li, L-Y
    RESPIROLOGY, 2011, 16 : 146 - 146
  • [22] Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer
    Chen, Jing
    Gu, Runxia
    Wang, Qiong
    Dassarath, Meera
    Yin, Zhongyuan
    Yang, Kunyu
    Wu, Gang
    ONKOLOGIE, 2012, 35 (09): : 509 - 513
  • [23] Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
    R. B. Verheijen
    T. T. van Duijl
    M. M. van den Heuvel
    D. Vessies
    M. Muller
    J. H. Beijnen
    J. M. Janssen
    J. H. M. Schellens
    N. Steeghs
    D. van den Broek
    A. D. R. Huitema
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 269 - 276
  • [24] Monitoring of EGFR mutations in circulating tumor DNA of non-small cell lung cancer patients treated with EGFR inhibitors
    Verheijen, R. B.
    van Duijl, T. T.
    van den Heuvel, M. M.
    Vessies, D.
    Muller, M.
    Beijnen, J. H.
    Janssen, J. M.
    Schellens, J. H. M.
    Steeghs, N.
    van den Broek, D.
    Huitema, A. D. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (02) : 269 - 276
  • [25] 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    Pallis, A. G.
    Voutsina, A.
    Kalikaki, Ar
    Souglakos, J.
    Briasoulis, E.
    Murray, S.
    Koutsopoulos, A.
    Tripaki, M.
    Stathopoulos, E.
    Mavroudis, D.
    Georgoulias, V.
    BRITISH JOURNAL OF CANCER, 2007, 97 (11) : 1560 - 1566
  • [26] ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    A G Pallis
    A Voutsina
    Ar Kalikaki
    J Souglakos
    E Briasoulis
    S Murray
    A Koutsopoulos
    M Tripaki
    E Stathopoulos
    D Mavroudis
    V Georgoulias
    British Journal of Cancer, 2007, 97 : 1560 - 1566
  • [27] Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
    Heon, Stephanie
    Yeap, Beow Y.
    Britt, Gregory J.
    Costa, Daniel B.
    Rabin, Michael S.
    Jackman, David M.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2010, 16 (23) : 5873 - 5882
  • [28] Uncommon EGFR mutations in advanced non-small cell lung cancer
    O'Kane, Grainne M.
    Bradbury, Penelope A.
    Feld, Ronald
    Leighl, Natasha B.
    Liu, Geoffrey
    Pisters, Katherine -M.
    Kamel-Reid, Suzanne
    Tsao, Ming S.
    Shepherd, Frances A.
    LUNG CANCER, 2017, 109 : 137 - 144
  • [29] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Leah Wells
    Angel Qin
    Current Treatment Options in Oncology, 2023, 24 : 1802 - 1814
  • [30] EGFR mutations in non-small cell lung cancer - Clinical implications
    Charpidou, Andriani
    Blatza, Despoina
    Anagnostou, Elsa
    Syrigos, Konstantinos N.
    IN VIVO, 2008, 22 (04): : 529 - 536
12345